# Adjustment of Chemotherapy Duration in Follicular Lymphoma According to Minimal Residual Disease Status

> **NCT04934930** · PHASE2 · UNKNOWN · sponsor: **Meir Medical Center** · enrollment: 40 (estimated)

## Conditions studied

- Follicular Lymphoma

## Interventions

- **DRUG:** Bendamustin
- **DRUG:** Obinutuzumab

## Key facts

- **NCT ID:** NCT04934930
- **Lead sponsor:** Meir Medical Center
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2020-01-29
- **Primary completion:** 2025-08-01
- **Final completion:** 2025-08-01
- **Target enrollment:** 40 (ESTIMATED)
- **Last updated:** 2021-06-22

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04934930

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04934930, "Adjustment of Chemotherapy Duration in Follicular Lymphoma According to Minimal Residual Disease Status". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT04934930. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*